CRISPR 2.0, the Next Generation


History was made this year when the first FDA-approved CRISPR-based gene editing therapy became available to patients, designed to cure sickle cell anemia. That represents ground-breaking progress, but the treatment involves a months-long ordeal with often-brutal side effects and it is hugely expensive. With dozens of CRISPR therapeutics in the second phase of human trials, hopes run high that next-generation approaches will be easier and cheaper to deliver and more patient friendly. The payoff could be major progress in treating blood disorders, cardiovascular disease, cancer, and infectious diseases.

  • 2024 Health

Explore More


125 ideas
Sorry, we couldn't find any results
Clear filters

Thank you for signing up!

Please provide a valid email address.

Please provide a valid email address.
aerial 2019 campus
Sign up to receive the latest news from Aspen Ideas.